Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/27/25
End: 04/01/29
Due: 04/01/30
Phase: N/A
Priority: Normal
Start: 04/27/23
End: 01/09/25
Due: 01/09/26
Phase: N/A
Priority: Normal
Start: 05/14/21
End: 11/20/23
Due: 11/20/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer. | NCT06844357 | Zhejiang Raygene Pharmaceuticals Co., Ltd | user2@example.com | None | 2025-03-27 | 2029-04-01 | 2030-04-01 | - | - | 2025-07-14 |
| TATE and KN046 in MCRC | NCT06834399 | Zhejiang Raygene Pharmaceuticals Co., Ltd | user2@example.com | None | 2023-04-27 | 2025-01-09 | 2026-01-09 | - | - | 2025-07-14 |
| Evaluate the Effect of Tirazamine on Primary Liver Cancer. | NCT06848556 | Zhejiang Raygene Pharmaceuticals Co., Ltd | user2@example.com | None | 2021-05-14 | 2023-11-20 | 2024-11-20 | - | - | 2025-07-14 |